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Abstract
Handgrip strength is a widely used measure of muscle strength and a predictor of a range of
morbidities including cardiovascular diseases and all-cause mortality. Previous genomewide association studies of handgrip strength have focused on common variants primarily in
persons of European descent. We aimed to identify rare and ancestry-specific genetic variants associated with handgrip strength by conducting whole-genome sequence association
analyses using 13,552 participants from six studies representing diverse population groups
from the Trans-Omics in Precision Medicine (TOPMed) Program. By leveraging multiple
handgrip strength measures performed in study participants over time, we increased our
effective sample size by 7–12%. Single-variant analyses identified ten handgrip strength
loci among African-Americans: four rare variants, five low-frequency variants, and one common variant. One significant and four suggestive genes were identified associated with
handgrip strength when aggregating rare and functional variants; all associations were
ancestry-specific. We additionally leveraged the different ancestries available in the UK Biobank to further explore the ancestry-specific association signals from the single-variant
association analyses. In conclusion, our study identified 11 new loci associated with handgrip strength with rare and/or ancestry-specific genetic variations, highlighting the added
value of whole-genome sequencing in diverse samples. Several of the associations identified using single-variant or aggregate analyses lie in genes with a function relevant to the
brain or muscle or were reported to be associated with muscle or age-related traits. Further
studies in samples with sequence data and diverse ancestries are needed to confirm these
findings.

Introduction
Handgrip strength is an accessible measure of muscle strength and is used as a proxy of muscular fitness. It is quantified by measuring the amount of static force that the hand can squeeze
around a dynamometer. Handgrip strength varies by age, and men have greater handgrip
strength than women at all ages [1, 2]. For both men and women, peak handgrip strength is
observed in the fourth decade followed by a gradual decline with age. Handgrip strength is a
predictor of a range of morbidities including cardiovascular disease and all-cause mortality
[3], is a marker of frailty [4, 5] and a key component of sarcopenia [6]. Handgrip strength is
considered a marker of healthy aging [7–9]. It has been reported to be associated with both
overall and exceptional survival in men [10, 11] and may also be a marker of brain health [12–
14].
Heritability of handgrip strength, estimated by twin studies, is high (h2 = 30–65%) [15–17].
However, few genome-wide association studies (GWAS) have been conducted for handgrip
strength. A large and well-powered handgrip strength GWAS (N = 195,180 European participants) combined data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium and the UK Biobank (UKBB) and detected 16 genome-wide
significant (P<5×10−8) loci associated with handgrip strength [18]. A more recent and larger
GWAS was performed in 223,315 participants from the UKBB but analyzed a different phenotype, the relative handgrip strength, defined as the average of measurements of right and left
hand divided by weight [19]. The handgrip strength GWAS conducted to date included
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European-ancestry participants and did not leverage the multiple observations of handgrip
strength available in some studies. The genetic associations of the natural variation in handgrip
strength could help understanding the biological mechanisms of aging.
We aimed to identify genetic variants (specifically rare and ancestry-specific variants) associated with handgrip strength using multi-ancestry samples and whole genome sequence data
from the National Heart, Lung and Blood Institute (NHLBI) Trans-Omics in Precision Medicine (TOPMed) Program. Leveraging multi-ancestry samples can improve our understanding
of a trait by identifying novel variants that are not common in all populations. For studies
where multiple handgrip strength observations over time per person were available, we leveraged this information to increase the effective sample size. We compared three different methods for incorporating multiple measures of handgrip strength per person (one handgrip
strength observation close to age 60 years vs the mean of all handgrip strength observations vs
inclusion of all handgrip strength observations and accounting for correlations between multiple measurements). We additionally leveraged the different ancestries available in the UKBB
to further explore the ancestry-specific association signals identified in TOPMed.

Materials and methods
Populations and participants
The study design included TOPMed participants from six cohorts who had handgrip strength
measurements available: the Old Order Amish study, the Atherosclerosis Risk in Communities
(ARIC) Study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS),
the Hypertension Genetic Epidemiology Network (HyperGEN) and the Women’s Health Initiative (WHI). Descriptions of each cohort are available in S1 File. These participants represented six study-reported population groups: Non-Hispanic Whites/European-Americans
(EA), Non-Hispanic Blacks/African-Americans (AA), Hispanics/Latinos, Asians/PacificIslanders, American-Indian/Alaskan-Native, and Other.

Handgrip strength harmonization
The number of handgrip strength measures from multiple visits per study participant varied
across studies (ranging from one to nine). Details on the handgrip strength measurement protocol for each study are available in S1 File. For each exam with a handgrip strength measure,
we selected the maximum value for each participant. This approach is the standard handgrip
strength protocol used in many epidemiological and GWAS studies [1, 2, 18, 20]. We removed
weak handgrip strength observations (< 5kg) that were more likely to be measurement errors
than real values. In addition, for studies with handgrip strength available at multiple study visits (FHS, CHS and WHI), we removed outliers (|minimum or maximum handgrip strength—
mean handgrip strength| > 20kg by participant). In total, we removed 123 observations (weak
value or outliers). The final sample size consisted of 13,552 unique participants contributing
36,872 handgrip strength observations.

Whole genome sequencing
The NHLBI TOPMed program provided whole genome sequence (WGS), performed at an
average depth of 38× by several sequencing centers (New York Genome Center; Broad Institute of MIT and Harvard; University of Washington Northwest Genomics Center; Illumina
Genomic Services; Psomagen, Inc.; and Baylor Human Genome Sequencing Center), using
DNA from blood. Details regarding the laboratory methods, data processing and quality control are described in Taliun et al. [21] and in documents included in each TOPMed accession

PLOS ONE | https://doi.org/10.1371/journal.pone.0253611 July 2, 2021

3 / 19

PLOS ONE

Lung, and Blood Institute, National Institutes of
Health, U.S. Department of Health and Human
Services through contracts HHSN268201600018C,
HHSN268201600001C, HHSN268201600002C,
HHSN268201600003C, and
HHSN268201600004C. HyperGEN: The HyperGEN
Study is part of the NHLBI Family Blood Pressure
Program; collection of the data represented here
was supported by grants U01 HL054472 (MN
Lab), U01 HL054473 (DCC), U01 HL054495 (AL
FC), and U01 HL054509 (NC FC). The HyperGEN:
Genetics of Left Ventricular Hypertrophy Study was
supported by NHLBI grant R01 HL055673 with
whole-genome sequencing made possible by
supplement -18S1. Individual grants Dr. Jeffrey R.
O’Connell grant U01 HL137181 NIH grant
U24AG051129 awarded by the National Institute
on Aging (NIA). UK Biobank This research has
been conducted using the UK Biobank Resource
under Application Number 42614. The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: Dr. Bruce Psaty
serves on the Steering Committee of the Yale Open
Data Access Project funded by Johnson &
Johnson. This does not alter our adherence to
PLOS ONE policies on sharing data and materials.
The other co-authors do not have conflicts of
interest to declare.

TOPMed whole genome sequence association analysis of handgrip strength

released on the database of Genotypes and Phenotypes (dbGaP). Processing of whole genome
sequences was harmonized across genomic centers using a standard pipeline [22]. This study
utilized genotypes from TOPMed ‘freeze 8’ that comprised 186K samples, although fewer
actual participants were included based on the availability of handgrip strength measures. Variant discovery and genotype calling were performed jointly across TOPMed and Center for
Common Disease Genetics (CCDG) studies for all samples using the GotCloud pipeline [23].
A support vector machine quality filter was trained using known variants (positive training
set) and Mendelian-inconsistent variants (negative training set). The TOPMed Data Coordinating Center performed additional quality control checks for sample identity issues including
pedigree errors, sex discrepancies, and genotyping concordance. The reads were aligned to
human genome build GRCh38 using a common pipeline across all centers. After site level filtering, TOPMed freeze 8 consisted of 1.02B variants (single nucleotide variants (SNVs) and
short insertion-deletion (Indels) variants). As the analysis methods we use require no missing
genotype data, we included in our analyses genotypes with a low depth (less than 10-fold average depth) rather than imputing them to the mean, as is done by most software. The genotype
files were coded using the same reference allele for all studies and ancestries and the “minor”
allele was defined based on the overall allele frequency in TOPMed.

Principal Component Analyses (PCA) and relatedness estimates
PCA and relatedness (IBD) estimates were made for 140,062 TOPMed samples using 638,486
SNVs passing QC, linkage disequilibrium (LD)-pruned from the genotypes with minimal
depth >10× with a minor allele frequency (MAF) threshold of 0.01 (where “minor” allele is
defined based on overall allele frequency in all of TOPMed), a missing call rate (MCR) threshold of 0.01 and a LD threshold of 0.32. The ancestral principal components (PCs) data were
created by running the GENetic EStimation and Inference in Structured samples (GENESIS)
R package ’pcair’ function [24]. PC-AiR partitions samples into ‘unrelated’ and ‘related’ sets
based on genotypes and then performs PCA on the ‘unrelated’ set, and finally projects PC values for the ‘related’ set [25]. A threshold of 2^(-9/2) as inferred by the KING ibdseg algorithm
[26] was used for defining the ‘unrelated’ set, meaning that a set of samples less related than
3rd degree was used to calculate the PCs. Relatedness was estimated using the GENESIS R
package ’pcrelate’ function [24], which estimates kinship coefficients and IBD sharing probabilities conditional on ancestry [27]. The resulting relatedness matrix includes pairwise kinship
estimates for all samples, not just those used to calculate PCs. After reviewing the PCA plots as
well as the PC-SNP correlation plots, we determined that PCs 1–11 detected ancestry among
the TOPMed freeze 8 samples, and included PCs 1–11 in all analysis models, as recommended
by the TOPMed Data Coordinating Center (for an example from an earlier TOPMed data
freeze, see Extended Data Fig 1 in Taliun et al. 2021 [21]).

Association analyses in TOPMed
Harmonized handgrip strength data were pooled across six studies and WGS association analysis of handgrip strength was performed using GENESIS on the Analysis Commons [28]. For
our primary model of handgrip strength outcome (MEAN), we computed the mean of the
maximum handgrip strength observations across exams for each individual and the mean
covariate values. When height or weight information was not available at one exam, we
imputed it based on the closest exams where the information was available (~1.2% of CHS participants, and ~5% of FHS participants). We used linear mixed effects models to test the association of handgrip strength with the genetic variants individually, while adjusting for age at
handgrip strength measurement, age at handgrip strength measurement2, sex, height, body
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mass index (BMI), study, interaction of age, BMI and study with sex, and 11 PCs, allowing for
heterogeneous variance across study groups [29]. The adjustment for study accounted for any
differences due to differing study design. For studies with different mixes of ancestries, it also
partially adjusted for ancestry. The inclusion of PCs in the model, in addition to study,
adjusted for the residual population structure in the studies. We accounted for relatedness
using a dense empirical kinship matrix. For the X chromosome, genotypes were coded as 0
and 2 for men and 0, 1 and 2 for women.
We compared our primary analysis (MEAN) with two additional models of handgrip
strength outcome: one model where we selected handgrip strength at the visit where a participant’s age was close to 60 years (ONE), and one model where we used all available visits when
a participant had handgrip strength measures performed (ALL). For the latter, we conducted
analyses using Generalized Linear Mixed Model Association Tests (GMMAT) [30] for variants
with a MAF greater or equal to 0.001 with a random intercept to account for the correlations
of handgrip strength measures from the same individuals across visits. To compare the three
analysis strategies, we calculated correlations of effect sizes and P-values for each SNV from
the three different models of handgrip strength. The handgrip strength phenotypic correlation
between the MEAN and the ONE analysis was equal to 0.96, 0.95 and 0.93 for FHS, WHI and
CHS respectively.
To estimate the impact of using multiple handgrip strength measures on the sample size,
we calculated an effective sample size (Neff) using two different methods. We first calculated
variance ratios between analyses leveraging multiple observations (ALL or MEAN) versus one
(ONE). We also calculated a participant effective sample size using: neff ¼ 1þðn n 1Þ�r with ρ
being the study-specific mean of the maximum correlation observed across visits in men and
women (as men and women had different pairwise correlations), and n being the number of
handgrip strength observations for the participant. When ρ approaches 1, neff shrinks toward 1
and Neff = ∑neff shrinks towards the total number of participants (N). As the maximum correlation observed across exams was used, this method may have underestimated the true effective sample size.
The effect allele frequency (EAF) was estimated in the relevant group used in the analyses.
The minor allele count (MAC) was derived based on the sample size (N) and the MAF (i.e.,
MAC = 2×N×MAF), where the MAF was defined as the EAF if EAF<0.50 and 1-EAF if EAF>
= 0.50. Single-variant association analyses excluded variants with a minor allele count (MAC)
less than 20. We used a significance threshold of P < 2×10−8 to report an association as
genome-wide significant, which was slightly more stringent than the widely adopted P-value
threshold of 5×10−8 in GWAS, based on estimations for genome-wide significance for WGS
studies in UK10K [31].
For the main analysis (MEAN), we additionally performed ancestry-specific analyses (analyses conducted separately in EA and AA, the two population groups with the largest sample
sizes) and sex-stratified analyses (analyses conducted separately in men and women). The het2

ðbmen bwomenÞ
erogeneity test between men and women was calculated using: SEmen2 þSEwomen
2 2�r�SEmen�SEwomen
that assessed the difference in effect sizes between men (βmen) and women (βwomen) while
accounting for correlation (r) due to relatedness, calculated using the genome-wide correlation
of the effect sizes in men and women.
We also performed gene-based tests with SKAT-O using GENESIS [32] for variants with a
MAC greater or equal to 2 and a MAF lower than 0.01. We performed analyses in the pooled
sample as well as stratified by ancestry, as rare variant aggregation tests can be underpowered
for identifying rare variant associations in admixed populations [33]. We aggregated variants
in GENECODE (v28) genes using three successively less stringent criteria: high confidence
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loss of function (hcLoF) based on Loss-Of-Function Transcript Effect Estimator [https://
github.com/konradjk/loftee], loss of function (LoF), or LoF and missense variants combined,
based on Variant Effect Predictor (VEP) Ensembl Consequence [34]. We also tested the association of aggregated variants by a fourth strategy which enriched for likely deleterious variants
in protein coding genes by retaining variants which were 1) hcLoF or 2) missense and predicted to be deleterious (by either SIFT4G [35], Polyphen2 (HDIV or HVAR) [36], or LRT
[37]) or 3) for which VEP Ensembl Consequence has the terms inframe_insertion or inframe_deletion, and which have Functional Analysis through Hidden Markov Models (fathmm
[38]) XF coding_score >0.5 (pathogenic mutations). The annotation based variant filtering
and gene-based aggregation was performed using TOPMed freeze 8 WGSA Google BigQuery
annotation database on the BiodataCatalyst powered by Seven Bridges platform [https://
biodatacatalyst.nhlbi.nih.gov/]. The annotation database was built using variant annotations
generated by Whole genome Sequence annotator version v0.8 [39] and formatted by WGSAParsr version 6.3.8 [https://github.com/UW-GAC/wgsaparsr]. We used a significance threshold of P < 5×10−7 to report a gene as genome-wide significant, which corresponded to a
Bonferroni correction for the number of genes tested and the number of analyses performed.
Only genes with a total MAC greater than or equal to 5 were analyzed.

Association analyses in the UKBB
The UKBB was used as an independent sample for external validation of our findings. The
UKBB is a prospective cohort study with deep genetic and phenotypic data collected on
approximately 500,000 individuals from across the United Kingdom, aged between 40 and 69
at recruitment [40]. The centralized analysis of the genetic data, including genotype quality,
population structure and relatedness of the genetic data, and efficient phasing and genotype
imputation has been described extensively elsewhere [40]. Two similar arrays were used for
genotyping (Applied Biosystems UK Biobank Lung Exome Variant Evaluation and UK Biobank Axiom Arrays) and pre-phasing was performed using markers present on both arrays.
Phasing on the autosomes was carried out using SHAPEIT3 [41] and 1000 Genomes phase 3
panel to help with the phasing of non-European ancestry samples. Imputations were carried
out using the IMPUTE4 program [40] with the Haplotype Reference Consortium (HRC) reference panel or with a merged UK10K and 1000 Genomes phase 3 reference panel when a variant was not present in HRC. For chromosome X, haplotype estimation and genotype
imputation were carried out separately on the pseudo-autosomal and non-pseudo autosomal
regions. The top 40 ancestral PCs were generated using fastPCA [42], a set of 407,219 unrelated participants with high quality samples and 147,604 high quality markers pruned to minimize LD. The corresponding PCs-loadings were then computed, and all samples were
projected onto the PCs, thus forming a set of PC scores for all samples in the cohort.
UKBB African-ancestry participants were identified using the following six self-reported
ancestries: "Caribbean", "African", "Black or Black British", "Any other Black background",
"White and Black African" and "White and Black Caribbean". We identified UKBB Europeanancestry participants using the following three self-reported ancestries: “White”, “British”, and
“Irish”. Handgrip strength in the UKBB was measured at three exams but the majority of the
participants had handgrip strength measured at only the first exam so we used only the first
exam. We excluded participants with a weak handgrip strength (< 5kg), and samples with
high heterozygosity and high missing rate, sex aneuploidy, and with different genomic and
stated sex. We used the Scalable and Accurate Implementation of Generalized mixed model
(SAIGE) [43] and linear mixed effect models to evaluate the variants that were associated with
handgrip strength in TOPMed, adjusting for age at handgrip strength measurement, age at
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handgrip strength measurement2, sex, height, BMI, age×sex, BMI×sex, and PCs significantly
associated with handgrip strength, and using an empirical kinship matrix.

Evaluation of previously published handgrip strength GWAS signals
We performed a look-up of the 1,452 SNVs that passed the genome-wide threshold in the
UKBB handgrip strength GWAS (Stage 1) [18] in our TOPMed analyses and calculated the
correlations of the effect sizes and frequencies of the effect alleles between the UKBB handgrip
strength GWAS and the TOPMed WGS.

Assessment of expression or methylation quantitative trait loci
We investigated whether the genetic variants from the handgrip strength UKBB GWAS or the
primary MEAN TOPMed handgrip strength WGS were expression or methylation quantitative trait loci (eQTLs / meQTLs) in human skeletal muscle using publicly available results
from the FUSION study [44].

Ethic statement
The data across the following studies were shared through the database of Genotype and Phenotype (dbGaP) exchange area. The study was approved by the appropriate institutional
review boards (IRB) and informed consent was obtained from all participants. Amish: All
study protocols were approved by the IRB at the University of Maryland Baltimore. Informed
consent was obtained from each study participant. ARIC: The ARIC Study has been approved
by IRB at all participating institutions: University of North Carolina at Chapel Hill, Johns Hopkins University, University of Minnesota, and University of Mississippi Medical Center. Study
participants provided written informed consent at all study visits. CHS: All CHS participants
provided informed consent, and the study was approved by the IRB or ethics review committee of University Washington. FHS: The Framingham Heart Study was approved by the IRB of
the Boston University Medical Center. All study participants provided written informed consent. HyperGEN: All HyperGEN participants provided informed consent, and the study was
approved by the IRB of the University of Kentucky. WHI: All WHI participants provided
informed consent and the study was approved by the IRB of the Fred Hutchinson Cancer
Research Center.

Results
Populations and participants
WGS association analysis of handgrip strength included 13,552 TOPMed participants. The
majority of these participants belonged to two major population groups: EA (N = 10,263; 76%)
and AA (N = 3,145; 23%) (Table 1). Around 1% of the sample belonged to other population
groups (Hispanic or Latino, Asian or Pacific-Islander, American-Indian or Alaskan-Native, or
other). Additional descriptive tables of the participants are presented in S1–S4 Tables in S1
File. Mean age (SD) of participants was 69 years (14) and mean handgrip strength (SD) was
29.4 kg (11.2). A total of 4,878 participants (36%) were men. Mean handgrip strength (SD) was
equal to 23.5 kg (6.5) in women and 40.1 (9.9) in men. Mean age (SD) was 71 years (11) in EA
participants and 60 years (18) in AA participants. Mean handgrip strength was equal to 28.9
kg (10.9) in EA participants and 31.6 kg (11.9) in AA participants.
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Table 1. Description of the 13,552 TOPMed participants included in the main pooled whole genome sequence association analysis of MEAN handgrip strength and
the 8,408 UK Biobank participants used for replication.
UKBB AAa

TOPMED
N (%)

a

a

a

TOTAL

EA

AA

Other

MEN

WOMEN

TOTAL

13,552 (100)

10,263 (76)

3,145 (23)

144 (1)

4,878 (36)

8,674 (64)

8,408 (100)

Age (years), mean (SD)

69 (14)

71 (11)

60 (18)

76 (6)

68 (14)

69 (14)

52 (8)

Height (cm), mean (SD)

165 (9.4)

165 (9.5)

166 (9.3)

158 (6.5)

174 (6.9)

160 (6.5)

168 (9)

BMI (kg/m2), mean (SD)

28.4 (5.8)

27.7 (5.2)

30.9 (7.0)

27.6 (5.3)

28.2 (4.8)

28.6 (6.3)

29.3 (5.4)

Handgrip strength (kg), mean (SD)

29.4 (11.2)

28.9 (10.9)

31.6 (11.9)

21.4 (7.2)

40.1 (9.9)

23.5 (6.5)

34.0 (11.7)

Mean covariates were calculated across all exams for which handgrip strength was available for the MEAN analysis.
EA: White/European-American; AA: Black/African-American/African-ancestry; Other: Hispanic or Latino (N = 107), Asian or Pacific-Islander (N = 17), American-

a

Indian or Alaskan-Native (N = 8), or other (N = 12).
b

We identified UKBB African-ancestry participants using the following six self-reported ancestries: "Caribbean", "African", "Black or Black British", "Any other Black
background", "White and Black African" and "White and Black Caribbean".
https://doi.org/10.1371/journal.pone.0253611.t001

Main single-variant analyses results
Manhattan plots and Quantile-Quantile plots for the main analysis (MEAN) are included in S1
and S2 Figs in S1 File. We observed a slight inflation of type I error (λGC = 1.08), despite having adjusted for potential sources of heterogeneity, cryptic relatedness, and population structure. This genomic inflation factor, computed at the median, was not extreme and within the
range of many published GWAS of densely typed variants with mixed ancestries. We detected
rare or low-frequency signals in ten regions at the genome-wide significance threshold
(P<2×10−8) in at least one analysis (pooled sample of 13,552 participants, ancestry-specific, or
sex-specific analyses for the MEAN handgrip strength outcome model). The most significant
variant in each region is indicated in Table 2 and S5 Table in S1 File. All signals were specific
to AA, the variants being too rare in EA to be tested in that subgroup alone. We identified a
region in 8p12 with a variant (rs2958754) common in AA (MAF = 0.10) but rare in EA
(MAF = 0.001), and with the highest association in women (S5 Table in S1 File, P = 1.3×10−8).
Table 2. Main association results from the WGS association analysis of MEAN handgrip strength (P<2×10−8 in at least one analysis) in the pooled sample of 13,552
TOPMed participants, or stratified by study-reported population groups (AA), and by sex (AA men and AA women).
TOTAL (N = 13,552)
Chr Pos (build 38)

rsid

Ref Alt
A

P

AAa (N = 3,145)
EAF

Beta
3.95

P

EAF

Beta

7.5E-08 0.018

6.21

P

AA WOMEN
(N = 2,158)
EAF

Beta

P

Gene

2.5E-04 0.018

2.55

4.0E-04

PLCL1

EAF

Beta

0.004

3.84

T

0.003

-2.84 5.1E-04 0.013 -3.14 3.8E-04 0.011 -13.10 1.5E-08 0.014 -0.51 5.4E-01

A

0.0008 -8.66 8.0E-09 0.003 -7.63 3.5E-06 0.006

G

6.4E-09 0.018

AA MEN (N = 987)

2

198,070,149

rs74688411

5

76,919,524

rs57776684b

C

5

174,630,802

rs377692678

G

7

95,524,137

rs544430450

G

A

0.001

-6.66 1.7E-08 0.006 -6.10 2.2E-06 0.006

-6.00

4.1E-02 0.006 -5.62 1.9E-05

ASB4

8

30,273,968

rs2958754 b

G

A

0.023

-1.28 1.0E-05 0.096 -1.27 1.1E-04 0.085

-0.19

8.2E-01 0.101 -1.55 1.7E-06

intergenic

10

85,774,936

rs569475444 b

G

C

0.005

-1.76 5.5E-03 0.022 -1.80 9.1E-03 0.024

-8.16

9.4E-08 0.021

0.97

1.6E-01

GRID1

10

119,692,415

rs189542078 b

C

T

0.001

5.36

1.0E-04 0.005

-1.08

7.5E-01 0.006

6.29

8.3E-07

intergenic

11

113,977,732

rs182799368 b

G

T

0.003

-3.13 4.2E-05 0.013 -3.07 2.3E-04 0.016

-9.19

2.0E-07 0.012

0.06

9.4E-01

HTR3A

14

96,043,941

rs143569685 b

T

A

0.003

-3.57 8.1E-07 0.014 -3.57 8.0E-06 0.013

-2.31

2.4E-01 0.015 -3.93 4.3E-07 C14orf132

18

71,404,509

rs185725127

A

C

0.001

-6.92 1.4E-09 0.006 -6.52 1.9E-07 0.006

-7.21

1.6E-02 0.006 -5.97 2.6E-06

1.0E-05 0.005

5.16

-8.98

3.2E-03 0.002 -6.03 4.0E-03

S100Z
intergenic

intergenic

EAF: Effect allele Frequency; Alt: Alternate (Effect) allele; Pos: Positions in build GRCh38; Beta: effect size, unit (kg).
a

AA: Black/African American/African-ancestry participants.
SNP significant in sex-stratified analyses (S5 Table in S1 File).

b

https://doi.org/10.1371/journal.pone.0253611.t002
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We identified sex-specific signals (Phet<0.05) in six regions (S5 Table in S1 File). The most
heterogeneous associations in 5q13, 10q23 and 11q23 were genome-wide significant in men
but not significant in women.

Gene-based tests results
We detected one gene (SLCO1A2) associated with handgrip strength at the genome-wide significance level (P < 5×10−7) when aggregating hcLoF/LoF rare variants with a MAC � 2 and a
MAF <1% using SKAT-O. The association was EA-specific (Table 3). Among the six hcLoF
variants that contributed to the test, two frameshift mutations were associated with handgrip
strength in single-variant association analyses (12:21292255:AAC:A, delAC, rs777190986,
MAF = 0.0001, MAC = 3, P = 8.6×10−4 and 12:21306938:CTGTT:C, delTGTT, rs761787824,
MAF = 0.0002, MAC = 4, P = 2.6×10−6). Additionally, a total of four genes were suggestively
associated with handgrip strength (P < 10−5) in at least one analysis (all participants, EA only,
or AA only) when aggregating 1) hcLoF, 2) LoF, or 3) hcLoF, missense variants predicted to be
deleterious, and pathogenic indels (Table 3). One EA-specific association (C9orf43) was found
when aggregating hcLoF or LoF and was driven by a splice donor mutation (rs766369889,
MAF = 0.0002, MAC = 3, P = 1.4×10−6). Two EA-specific associations (ZNF593 and
GALNT17) were found when aggregating hcLoF, missense variants predicted to be deleterious,
and pathogenic indels. The first association (ZNF593) was driven by a missense variant
(rs2232649, MAF = 0.004, MAC = 112, P = 1.3×10−5). This variant has a MAF higher than 1%
in AA and thus it did not contribute to the gene-based test in AA only. The second association
(GALNT17) was driven by a missense variant (rs139969494, MAF = 0.001, MAC = 22,
P = 1.5×10−6). One AA-specific association (MRPL16) was found when aggregating hcLoF,
Table 3. Significant and suggestive genes (P<10−5) associated with MEAN handgrip strength in TOPMed when aggregating rare variants with a minor allele count
(MAC) greater or equal to 2 and a minor allele frequency (MAF) less than 1% using SKAT-O.
High confidence loss of function
(hcLoF) variants

LoF variants

LoF and missense variants

hcLoF, deleterious missense
variants and pathogenic indels

Gene

Groupa

n.site

n.alt

n.s.alt

P

n.site

n.alt

n.s.alt

P

n.site

n.alt

n.s.alt

P

n.site

n.alt

n.s.alt

P

ZNF593

Total

--

--

--

--

--

--

--

--

11

343

335

0.001

6

129

129

4.7E-06
0.01

MRPL16

SLCO1A2

GALNT17

C9orf43

EA

--

--

--

--

--

--

--

--

11

47

44

0.07

6

20

20

AA

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

Total

2

10

10

0.24

3

12

12

0.11

17

250

239

0.75

13

210

201

0.65

EA

2

9

9

0.15

3

11

11

0.06

14

92

90

0.34

11

86

84

0.36

AA

--

--

--

--

--

--

--

--

5

80

79

0.004

3

24

24

1.2E-06

Total

6

18

18

2.7E-07

6

18

18

2.7E-07

47

434

419

0.37

31

250

240

0.37

EA

4

10

10

1.3E-06

4

10

10

1.3E-06

31

148

148

0.12

20

77

77

0.02

AA

2

7

7

0.81

2

7

7

0.81

15

80

73

0.30

10

34

27

0.42

Total

--

--

--

--

--

--

--

--

19

279

278

0.03

14

98

98

3.1E-05

EA

--

--

--

--

--

--

--

--

12

81

81

1.1E-05

10

74

74

9.3E-06

AA

--

--

--

--

--

--

--

--

5

69

69

0.76

4

21

21

0.42

Total

3

9

9

1.0E-05

4

12

12

1.5E-05

28

409

404

0.21

14

63

63

0.05

EA

2

5

5

9.4E-06

2

5

5

9.4E-06

17

315

311

0.50

10

49

49

0.06

AA

--

--

--

--

2

7

7

0.46

13

131

130

0.80

4

30

30

0.46

n.site: the number of variant sites included in the test; n.alt: the number of alternate alleles included in the test; n.s.alt: the number of samples with an observed alternate
allele at any variant in the aggregate set.
–: no result (total minor allele count lower than 5).
EA: White/European-American; AA: Black/African-American/African-ancestry.

a

https://doi.org/10.1371/journal.pone.0253611.t003
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missense variants predicted to be deleterious, and pathogenic indels and was driven by a missense variant predicted to be deleterious by SIFT (rs147545257, MAF = 0.002, MAC = 15,
P = 6.8×10−7).

Comparison of handgrip strength outcome models and calculation of the
effective sample size
We observed very high correlations when comparing effect-sizes of variants with a MAF
greater or equal to 0.001 from the three different models of handgrip strength outcomes (r
ranging from 0.93 to 0.99). The correlations when comparing–log(P)-values were also high
but a bit lower, particularly when comparing the analysis leveraging one handgrip strength
observation (ONE) versus the analyses leveraging the multiple handgrip strength observations
(MEAN and ALL, r = 0.87 and 0.85 respectively). The highest correlation (r = 0.98 for–log(P)values and r = 0.99 for effect sizes) was observed when comparing ALL and MEAN, the two
models that leveraged the multiple handgrip strength observations (S3 and S4 Figs in S1 File).
Results of all signals reaching genome-wide significance with at least one model of handgrip
strength outcome (ALL, ONE and MEAN) and a MAF greater or equal to 0.001 are presented
in S6 Table in S1 File. All these signals had a P-value lower than 10−7 in the MEAN analysis.
We estimated that the effective sample size increase ranged between 7 and 12% when leveraging multiple handgrip strength observations and accounting for the correlations of the observations (S7 Table in S1 File).

Exploration of the main ancestry-specific TOPMed results in UKBB
We did not observe a significant association of the six low-frequency or common index variants associated with MEAN handgrip strength in TOPMed AA association analysis in UKBB
African-ancestry participants (N = 8,408; S8 Table in S1 File). Two of the six variants
(rs577776684 and rs569475444), which had a low-frequency in TOPMed AA, were rarer in the
UKBB African-ancestry participants.

Evaluation of previously published handgrip strength GWAS signals
Single-variant associations for the 16 index variants from the CHARGE+UKBB handgrip
strength GWAS [18] are presented in S9 Table in S1 File. We estimated that the power to
detect each of these 16 variants in our TOPMed sample, using significance level α = 0.05, ranged between 0.18 and 0.26, assuming that the variants explain the same proportion of variance
in our sample as in the GWAS discovery UKBB sample. In addition, a total of 1,452 SNVs
were genome-wide significant in the handgrip strength GWAS Stage 1 (UKBB only). We
observed a high concordance of the direction of effects between UKBB and TOPMed (98%
when including all participants in the TOPMed analysis, 99% when including only TOPMed
EA, and 92% when including only TOPMed AA). We observed a high concordance of the
effect sizes reported by the UKBB handgrip strength GWAS and TOPMed (correlation of 0.93
when including all TOPMed participants in the analysis or only EA, and of 0.69 when including only TOPMed AA in the analysis). We observed a difference in allele frequencies between
EA and AA for the handgrip strength UKBB GWAS results in TOPMed (S5 Fig in S1 File). A
total of 295 variants showed nominal significance (P<0.05) and 14 variants had a P-value less
than 0.001 in at least one TOPMed analysis (all participants, ancestry-specific, or sex-specific
analyses for the MEAN handgrip strength outcome model) (S10 Table in S1 File). The most
significant association was observed for the variant rs4793937 in 17q21 (P = 3.8×10−6) with a
higher effect in men compared to women.
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Assessment of expression or methylation quantitative trait loci
We investigated whether the 16 lead SNPs from the handgrip strength UKBB GWAS, the 14
SNPs from the handgrip strength UKBB GWAS with a P-value less than 0.001 in TOPMed,
and the 10 lead SNPs from the TOPMed handgrip strength WGS, were eQTLs or meQTLs in
human skeletal muscle. We found that 13 SNPs from the handgrip strength UKBB GWAS
were eQTLs (P<1×10−6) in 1p36 (PEX14), 2p21 (LRPPRC), 17q21 (HOXB cluster) and 17q25
(ACTG1). Interestingly, the allele associated with a higher handgrip strength was also associated with an increase in gene expression, except for rs6565586 in 17q25 (S11 Table in S4 File).
We found that all of these eQTLs were also meQTLs (P<1×10−6) except rs4245797 and we
identified additional meQTLs in 1p32, 2p22, 2p13, 10q24, 10q26, 11q25, and 12p12 (S12
Table in S4 File).

Discussion
This study is the first to report a WGS association analysis of handgrip strength in 13,552 participants from six studies representing diverse population groups. By leveraging multiple
handgrip strength observations per person over time, we increased our effective sample size by
7–12%. Using single-variant analyses, we identified 10 new loci influencing handgrip strength
with rare, low-frequency or common AA-specific associations. Using gene-based tests, we
identified one significant and four suggestive genes associated with handgrip strength when
aggregating rare and functional variants. These associations were ancestry specific.
Several genetic variants identified associated with handgrip strength using single-variant
association analysis or gene-based tests in TOPMed lie in genes with a function relevant to the
brain or muscle. We describe below the function of some of these genes.
Like the findings in Willems et al handgrip strength GWAS, two TOPMed handgrip
strength hits lie within genes with a function relevant to the brain. The genetic variant
rs569475444 lies in the intron of the glutamate ionotropic receptor delta type subunit 1 gene
(GRID1) that encodes a subunit of glutamate receptor channels and mediates most of the fast
excitatory synaptic transmission in the central nervous system and play key roles in synaptic
plasticity. It is mainly expressed in the brain (Genotype-Tissue Expression project, GTEx) and
sex-specific associations in this gene were reported with Alzheimer’s Disease risk [45]. Additionally, sex differences in the glutamate system have been described [46]. The genetic variant
rs182799368 lies in the intron of the 5-hydroxytryptamine receptor 3A gene (HTR3A) that
encodes the subunit A of the type 3 receptor for 5-hydroxytryptamine (serotonin), a biogenic
hormone that functions as a neurotransmitter, a hormone, and a mitogen. Variants in this
gene were reported to be associated with multiple sclerosis [47], a potentially disabling disease
of the brain and spinal cord causing numbness or weakness in one or more limbs, tremor, lack
of coordination or unsteady gait. Additionally, sex differences in serotonin synthesis rates have
been described in human brain [48]. Emerging evidence suggests that handgrip strength is
associated with better cognitive performance in patients with major depressive disorder
(MDD) and that stronger handgrip strength is associated with greater left and right hippocampal volume and reduced white matter hyperintensities in patients with MDD [14]. White matter hyperintensities are common, albeit mild, in middle adult life and are associated with
physical disability, possibly through reduced speed, fine motor coordination, and muscular
strength [49]. A correlation also exists between spinal white matter organization as determined
by diffusion tensor imaging and force control in precision grip, an important aspect of manual
dexterity in healthy subjects [50].
Other TOPMed handgrip strength hits lie within genes with a function relevant to muscle
or have reported associations with muscle or age-related traits.
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The genetic variant rs74688411 lies in the intron of the phospholipase C like 1 (PLCL1)
gene that has been reported by GWAS of adult and juvenile dermatomyositis [51], hip bone
size variation in women [52], and total bone mineral density [53]. Hip bone size and bone
mineral density are key measurable risk factors for low trauma hip fractures. Handgrip
strength is also a potentially useful objective parameter to predict fracture since it is an indicator of general muscle strength, is associated with fragility and propensity to fall, and is related
to fracture risk [54, 55]. Willems et al found genome-wide genetic correlations of bone mineral
density with handgrip strength, supportive of a role for genetically predicted handgrip strength
in fracture risk [18]. The genetic variant rs544430450 lies in the intron of the ankyrin repeat
and SOCS box containing 4 gene (ASB4) that colocalizes with the insulin receptor substrate 4
(IRS4) in the hypothalamic neurons and mediates IRS4 degradation [56]. Ankyrin repeat
domain containing proteins have a role in muscle physiology [57]. Indeed, many aspects of
muscle function are controlled by the superfamily ankyrin repeat domain containing proteins,
including structural fixation of the contractile apparatus to the muscle membrane by ankyrins,
the archetypical member of the family. Interestingly, this gene is highly and specifically
expressed in the adrenal gland (GTEx). Variants in the solute carrier organic anion transporter
family member 1A2 (SLCO1A2) have been reported to be associated with statin-induced
myopathy and progressive supranuclear palsy, an uncommon brain disorder that affects,
among others, movement, control of walking (gait) and balance. This gene is specifically
expressed in the brain (GTEx). The S100 calcium binding protein Z (S100Z) and the mitochondrial ribosomal protein L16 (MRPL16) genes were found to be significantly different
between non-frail and frail middle-aged individuals [58]. Variants in the polypeptide N-acetylgalactosaminyltransferase 17 gene (GALNT17) were reported associated with physical activity
[59].
We have compared our primary analysis, where all available handgrip strength measures
were averaged for each participant (MEAN), with two additional models: one model where the
handgrip strength measure at the exam close to 60 years old was analyzed for each participant
(ONE), and one model where all available handgrip strength measures were analyzed for each
participant (ALL). Each of these approaches has strengths and limitations. The ONE analysis
does not leverage the multiple handgrip strength measures and requires selecting one handgrip
strength exam. We decided to select the exam close to 60 years old for each participant to
investigate handgrip strength in older adults at a time when handgrip strength may be declining. Thus, this approach has a limited power. The MEAN analysis accounts for the variability
of handgrip strength measures across studies but does not account for the variability of handgrip strength measures within studies. A weighted analysis could be performed to account for
the number of measures for each participant within each study, but this approach is not implemented in GENESIS or GMMAT software available on the Analysis Commons. We do not
expect our results to drastically change when weights are incorporated in the model. The ALL
analysis may be the best model to leverage all available handgrip strength measures. However,
this approach is computationally intensive and may over-represent participants or studies with
a higher number of handgrip strength observations (such as CHS or WHI). To note, all signals
with a MAF greater or equal to 0.001 and reaching genome-wide significance (P<2×10−8)
with at least one model of handgrip strength outcome had a P-value lower than 10−7 in the
MEAN analysis (S6 Table in S1 File).
None of our TOPMed findings were found to be eQTLs or meQTLs in human skeletal muscle. However, the FUSION eQTL and meQTL study was performed in Finnish participants
whereas our signals were almost all specific to AA. Availability of eQTLs or meQTLs data in
African-ancestry participants is limited.
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Strengths of this investigation include the analysis of extremely high-quality deep sequence
data from a large, multi-ancestry sample with multiple handgrip strength observations. We
included six studies with the majority of participants identified as Non-Hispanic Black/African-American or Non-Hispanic White/European-American. The high-quality sequence data
allowed us to assess association of handgrip strength with genetic variation across the full allelic spectrum.
We also recognize limitations. Our sample size, and thus our power, is limited compared to
previous large European-ancestry GWAS, but the WGS permits the investigation of less common and rare variants. Including larger samples of individuals, especially of non-European
population groups, will improve the characterization of the genetic architecture underlying
handgrip strength. We used a slightly more stringent threshold to report genome-wide significant findings than the widely adopted GWAS P-value threshold of 5×10−8, to account for the
higher number of variants tested (SNVs and insertions/deletions) but this threshold may still
be a bit anti-conservative due to the additional subgroup analyses performed. We view these
additional analyses as critical to understanding the observed associations. Finally, we have not
considered in this paper local ancestry analysis that could help to further investigate the effects
of the detected variants and ancestry-gene interaction that could boost statistical power of rare
variant association mapping in admixed populations.
The handgrip strength genome-wide associations in single-variant analyses that we
observed were AA-specific and some were also sex-specific. We observed associations with
consistent direction of effects in at least two studies for each signal (S13 Table in S1 File).
Given the large mean handgrip strength difference between men and women, we might expect
that handgrip strength may have at least some different genetic associations in men and
women. A recent GWAS of testosterone identified, for instance, extreme sex differences in testosterone genetic architecture [60].
Finding replication samples with ethnically diverse populations, handgrip strength information and sequence data is challenging. As no similar sample with WGS exists, we used
UKBB imputed genotype data to further explore our ancestry-specific findings. We could only
look-up the common or low-frequency AA-specific TOPMed signals in the UKBB Africanancestry participants, who were defined based on six different self-reported ancestries. We did
not observe significant associations of these variants with handgrip strength. There are several
possible explanations, including 1) genetic heterogeneity across the two samples, 2) age differences in the two samples (UKBB participants are 8 years younger on average than those in our
TOPMed sample, Table 1) 3) imputation in UKBB African ancestry samples may not be accurate for these low frequency variants, and 4) the effects we observed may be inflated due to
winners curse, and thus the power to detect the associations is limited in the UKBB African
ancestry sample. Because we do not have a sequenced replication sample from the same populations as our discovery sample, we cannot rule out the possibility that the associations identified in TOPMed could be false positives.
In conclusion, by leveraging multiple handgrip strength observations from a multi-ancestry
sample with sequence data, our study identified 11 new loci associated with handgrip strength
with rare and/or ancestry-specific genetic variations. Further studies in ethnically diverse populations are needed to confirm these findings.

Supporting information
S1 File. Materials.
(DOCX)

PLOS ONE | https://doi.org/10.1371/journal.pone.0253611 July 2, 2021

13 / 19

PLOS ONE

TOPMed whole genome sequence association analysis of handgrip strength

S2 File. Longevity wkgp list.
(XLSX)
S3 File. TOPMed banner authorship.
(XLSX)
S4 File. S11 and S12 Tables.
(XLSX)

Acknowledgments
TOPMed Longevity and Healthy Aging Working Group
Co-conveners: Joanne M Murabito, Kathryn L Lunetta, and Chloé Sarnowski.
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